TEM climbs almost 4% after ARK Invest share sale and regulatory news

Traders Union
All News
Stocks
Tempus AI surges 3.64% to $79.27 today

Highlights

ARK Invest sold 128,292 shares of Tempus AI from its ARKK ETF at September 29 closing prices, contributing to increased trading activity.
Tempus AI recently received FDA clearance for its ECG-MR tool, but the timeline for clinical adoption remains unspecified.
Tempus AI stock is showing robust upward momentum with support at $73.53 and is expected to trade between $72.65 and $85.56 over the next five sessions.

Share sale and regulatory news fuel post-clearance trading swings

ARK Invest sold 128,292 shares of Tempus AI via its ARKK ETF using September 29 closing prices. The transaction took place shortly after Tempus AI received FDA clearance for its ECG-MR tool, although clinical adoption timelines have not been specified. Both the share sale and the regulatory announcement contributed to heightened volatility in the shares.

Anton Kharitonov, expert at Traders Union, notes that bullish momentum in Tempus AI is clouded by pronounced volatility after ARK Invest’s sizeable share sale. He sees technically overbought conditions, with oscillators showing exhaustion even as the price holds above all key moving averages. Fundamental uncertainty remains on how quickly the FDA-cleared ECG-MR tool will translate into commercial results. Sentiment may reverse quickly, as institutional outflows often foreshadow corrections in high-momentum stocks. In his view, "Short-term upside remains vulnerable — a breakdown below $76.07 could trigger steeper losses for unsuspecting bulls."

Viktoras Karapetjanc, expert at Traders Union, highlights that Tempus AI maintains a constructive outlook after recent positive FDA news, despite ARK Invest’s exit. He believes the upward trend is reinforced by strong technical positioning and potential for rapid adoption of the newly cleared ECG-MR tool. Market structure remains bullish, with buy-side strength backed by supportive momentum indicators. He states, "Bullish structure remains intact above $76.07 and further growth is expected toward $85.56 as market participants recognize Tempus AI’s regulatory wins."

Jainam Mehta, market strategist, sees a tug-of-war in Tempus AI between bullish momentum signals and conflicting short-term oscillators. He notes that institutional actions and regulatory headlines could drive sharp swings in either direction. Mehta suggests watching for a potential breakout above $82.38 or a volatility-driven retest of $72.65 support. He advises, "Traders should stay tactical and look for contrarian setups if price reverts toward the lower end of the forecast range."

Momentum divergence emerges as oscillators flag short-term exhaustion

Tempus AI trades above its 20-day ($72.83), 50-day ($61.95), and 200-day ($56.41) moving averages, indicating bullish momentum across all timeframes and confirmation of a strong upward structure. The stock’s Ichimoku Kijun level at $73.53 now acts as technical support, with today’s near-term ceiling at $82.38 and the floor at $76.07. Daily momentum is positive, with both the MACD and ADX showing ongoing buy strength. RSI at 56.54 implies slightly bullish conditions, while Stochastic RSI at 15.61 reflects an oversold state. CCI is neutral, Bull/Bear Power (BBP) at 5.25 signals strong buyer dominance and overbought conditions, and the Awesome Oscillator (AO) is neutral relative to the trend. Several oscillators suggest a divergence, as strong underlying momentum is countered by short-term exhaustion signals.

Previously it was reported that Tempus AI held a broadly bullish structure despite persistent selling pressure following ARK Invest's share sale and FDA clearance for its ECG-MR tool. The current analysis not only reinforces that bullish momentum has persisted but also highlights that the prevailing scenario now hinges on whether the stock consolidates above $76.07 or accelerates toward the upper forecast boundary at $85.56.

Source of Data: TEM Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.